Advances in therapy · 2026
Racial and Ethnic Patterns Observed in Inflammatory Bowel Disease Prevalence, Clinical Burden, and Healthcare Resource Utilization in the United States: Findings from an Administrative Claims Database.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patel Aarti A, Ferrante Shannon, Sanon Myrlene, Kachroo Sumesh
Аннотация
INTRODUCTION: Inflammatory bowel disease (IBD) is a chronic, immune-mediated gastrointestinal disorder comprised of Crohn's disease (CD) and ulcerative colitis (UC). Real-world data on racial differences in disease burden, treatment patterns, and healthcare resource utilization (HCRU) remain limited.
METHODS: The retrospective observational study was conducted using Optum's de-identified Clinformatics® Data Mart Database (Optum® CDM) in the US. Data from adult patients with a diagnosis of CD and/or UC between January 1, 2010, and September 30, 2022, were extracted and analyzed to assess the prevalence of IBD, complicated/penetrating CD, and extraintestinal manifestations (EIMs) across different races/ethnicities in the US. The treatment use, HCRU, and symptomatic and psychosocial burden among patients pre-and post-IBD diagnosis were also assessed among patients stratified by race/ethnicity.
RESULTS: A total of 271,059 patients included in the analysis were predominantly White (76.6%) followed by Black (7.9%), Hispanic (6.1%), and Asian (2.6%). IBD prevalence rose from 0.5% (2010) to 2.2% (2022). In 2022, prevalence was highest among White (2.5%) followed by Black (1.9%), Asian (1.4%), and Hispanic individuals (1.3%). Among patients with CD and UC, respectively, EIM prevalence rose from 38.4% and 31.5% in 2016 to 57.5% and 43.2% in 2022. Corticosteroids and biologics were prescribed to 38.8% and 52.8% of patients with CD and UC post-diagnosis, respectively. IBD-related HCRU increased after diagnosis, particularly among acute care patients, and was highest in Black individuals.
CONCLUSION: The results highlight an increased prevalence of IBD among patients from different racial and ethnic backgrounds. The study further provides insights into the IBD-related outcomes, treatment use, and HCRU patterns among diverse racial and ethnic groups and underlines the present unmet need for further research.
METHODS: The retrospective observational study was conducted using Optum's de-identified Clinformatics® Data Mart Database (Optum® CDM) in the US. Data from adult patients with a diagnosis of CD and/or UC between January 1, 2010, and September 30, 2022, were extracted and analyzed to assess the prevalence of IBD, complicated/penetrating CD, and extraintestinal manifestations (EIMs) across different races/ethnicities in the US. The treatment use, HCRU, and symptomatic and psychosocial burden among patients pre-and post-IBD diagnosis were also assessed among patients stratified by race/ethnicity.
RESULTS: A total of 271,059 patients included in the analysis were predominantly White (76.6%) followed by Black (7.9%), Hispanic (6.1%), and Asian (2.6%). IBD prevalence rose from 0.5% (2010) to 2.2% (2022). In 2022, prevalence was highest among White (2.5%) followed by Black (1.9%), Asian (1.4%), and Hispanic individuals (1.3%). Among patients with CD and UC, respectively, EIM prevalence rose from 38.4% and 31.5% in 2016 to 57.5% and 43.2% in 2022. Corticosteroids and biologics were prescribed to 38.8% and 52.8% of patients with CD and UC post-diagnosis, respectively. IBD-related HCRU increased after diagnosis, particularly among acute care patients, and was highest in Black individuals.
CONCLUSION: The results highlight an increased prevalence of IBD among patients from different racial and ethnic backgrounds. The study further provides insights into the IBD-related outcomes, treatment use, and HCRU patterns among diverse racial and ethnic groups and underlines the present unmet need for further research.